Compare AbCellera Biologics Inc (ABCL) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs OneSpan Inc — how do they compare? AbCellera Biologics Inc trades at $10.1 (market cap $2.99B), while OneSpan Inc trades at $16.19 (market cap $600.69M). The key difference: AbCellera Biologics Inc is far larger — about 5× OneSpan Inc's market cap, and OneSpan Inc pays a 3.19% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | OSPN | |
|---|---|---|
Market Cap | $2.99B | $600.69M |
Sector | Health | Technology |
52-Week High | $9.76 | $16.78 |
52-Week Low | $2.78 | $10.15 |
Enterprise Value | $2.58B | $569.77M |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
OneSpan (OSPN) trades at $16.21, down 0.98% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with a P/E of 9.21, net income margin of 27.76%, and consistent earnings beats in recent quarters. Recent Q2 2026 results showed revenue growth and raised full-year guidance, while the company continues paying $0.13 quarterly dividends.
Outlook remains positive with 67% analyst buy ratings and $17 consensus target offering 5% upside. Key risks include declining net cash flow and competitive pressures in the software sector. The stock presents value opportunity given attractive valuation multiples and strong profitability metrics, though investors should monitor execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
